BTAI News and Press, BioXcel Therapeutics Inc. From 03/25/24

NEW HAVEN, Conn., March 25, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it h...

2024-03-21 11:53:17 ET More on S&P 500 Index: Chairman Powell Hits A Grand Slam Home Run Despite What The Fed Says, The Policy Is Still 'Higher-For-Longer' The Fed Is More Dovish Than The Market Anticipates 32 “Breakthroughs” stocks by BofA ...

NEW HAVEN, Conn., March 15, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today reported that the European Patent Office (EPO) granted the C...

2024-03-12 11:00:22 ET BioXcel Therapeutics, Inc. (BTAI) Q4 2023 Earnings Conference Call March 12, 2024 8:00 AM ET Company Participants Vimal Mehta - Chief Executive Officer Vince O'Neill - Chief of Product and Development Medical Officer Richard Steinhart - Chi...

2024-03-12 07:02:27 ET More on BioXcel Therapeutics UBS cuts BioXcel to neutral; cites regulatory issues, financing BioXcel Therapeutics announces termination of proposed public offering Seeking Alpha’s Quant Rating on BioXcel Therapeutics Historical e...

Koninklijke KPN NV (KKPNF) is expected to report for Q4 2023 ECA Marcellus Trust I Unit (ECTM) is expected to report for Q4 2023 San Juan Basin Royalty Trust (SJT) is expected to report for Q4 2023 Avenir Wellness Solutions Inc (AVRW) is expected to report for Q4 2023 Carmell Corp...

Provides update on two late-stage clinical programs for BXCL501 for potential treatment of agitation Recently completed meetings with U.S. Food and Drug Administration for TRANQUILITY and SERENITY programs C onference call and webcast set for 8:00 a.m. ET ...

2024-03-11 12:05:56 ET More on BioXcel Therapeutics UBS cuts BioXcel to neutral; cites regulatory issues, financing BioXcel Therapeutics announces termination of proposed public offering Seeking Alpha’s Quant Rating on BioXcel Therapeutics Historical e...

2024-03-11 05:50:46 ET More on related stocks: Oracle Q3 Earnings Preview: Cloud Computing Business In Focus Blink Charging: EV Tailwinds Offer A Path To Profitability In 2025 Ulta Beauty: We Are Not Adding To Our Position Before The Earnings Release (Rating Downgrad...

NEW HAVEN, Conn., March 01, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its fourth quarter and full y...